Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell – lineage antigen expression: experience from a tertiary cancer care center
Introduction: Flow cytometric immunophenotyping (FCI) plays a major role in diagnosing hematologic malignancies. In patients diagnosed with precursor B-lineage acute lymphoblastic leukemia (B-ALL), expression of certain non-lineage/cross lineage antigens is of prognostic and cytogenetic relevance. T...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-04-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137920302832 |
| _version_ | 1811252192887177216 |
|---|---|
| author | Karthik Bommannan Jhansi Rani Arumugam Venkatraman Radhakrishnan Jayachandran Perumal Kalaiyarasi Nikita Mehra Tenali Gnana Sagar Shirley Sundersingh |
| author_facet | Karthik Bommannan Jhansi Rani Arumugam Venkatraman Radhakrishnan Jayachandran Perumal Kalaiyarasi Nikita Mehra Tenali Gnana Sagar Shirley Sundersingh |
| author_sort | Karthik Bommannan |
| collection | DOAJ |
| description | Introduction: Flow cytometric immunophenotyping (FCI) plays a major role in diagnosing hematologic malignancies. In patients diagnosed with precursor B-lineage acute lymphoblastic leukemia (B-ALL), expression of certain non-lineage/cross lineage antigens is of prognostic and cytogenetic relevance. There is a paucity of studies that have comprehensively analyzed the clinical and laboratory profiles of B-ALL patients showing aberrant T/natural killer (NK) cell antigen expression. Materials and methods: This is a prospective study where 152 consecutive B-ALL patients were analyzed for aberrant expression of T/NK cell antigens (CD1a, CD5, CD4, CD7, CD8 and CD56) by FCI. The clinical and laboratory profile of these T/NK-cell antigen-expressing B-ALL patients was statistically analyzed against conventional B-ALL patients. Results: In our B-ALL cohort, CD5, CD7 and CD56 expression were observed in one, six and nine patients, respectively. CD56-expressing B-ALL patients were predominantly children (89%) and presented as standard clinical risk (p = 0.010) disease with frequent ETV6-RUNX1 fusion (p = 0.021) positivity. On the contrary, CD7-expressing B-ALL patients were adolescent-young adult/adult-age skewed (83%) and had an adverse cytogenetic profile (p = 0.001), especially for the frequent presence of BCR-ABL1 fusion (p = 0.004) and KMT2A rearrangement (p = 0.045). CD7-expressing B-ALL patients had inferior event-free survival (p = 0.040) than their CD56-expressing counterparts, but there was no significant difference in the overall survival (p = 0.317). Conclusion: In comparison to conventional B-ALL patients, there are significant differences in the age, cytogenetic profile and event-free survival of T/NK-cell antigen-expressing B-ALL patients. |
| first_indexed | 2024-04-12T16:31:12Z |
| format | Article |
| id | doaj.art-8aaebebff43d45b7a09dcf07c42ffbb7 |
| institution | Directory Open Access Journal |
| issn | 2531-1379 |
| language | English |
| last_indexed | 2024-04-12T16:31:12Z |
| publishDate | 2022-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj.art-8aaebebff43d45b7a09dcf07c42ffbb72022-12-22T03:25:08ZengElsevierHematology, Transfusion and Cell Therapy2531-13792022-04-01442143150Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell – lineage antigen expression: experience from a tertiary cancer care centerKarthik Bommannan0Jhansi Rani Arumugam1Venkatraman Radhakrishnan2Jayachandran Perumal Kalaiyarasi3Nikita Mehra4Tenali Gnana Sagar5Shirley Sundersingh6Corresponding author at: Department of Oncopathology, Cancer Institute (W.I.A,) Adyar, Chennai, 600020 India.; Cancer Institute (W.I.A.), Adyar, Chennai, IndiaCancer Institute (W.I.A.), Adyar, Chennai, IndiaCancer Institute (W.I.A.), Adyar, Chennai, IndiaCancer Institute (W.I.A.), Adyar, Chennai, IndiaCancer Institute (W.I.A.), Adyar, Chennai, IndiaCancer Institute (W.I.A.), Adyar, Chennai, IndiaCancer Institute (W.I.A.), Adyar, Chennai, IndiaIntroduction: Flow cytometric immunophenotyping (FCI) plays a major role in diagnosing hematologic malignancies. In patients diagnosed with precursor B-lineage acute lymphoblastic leukemia (B-ALL), expression of certain non-lineage/cross lineage antigens is of prognostic and cytogenetic relevance. There is a paucity of studies that have comprehensively analyzed the clinical and laboratory profiles of B-ALL patients showing aberrant T/natural killer (NK) cell antigen expression. Materials and methods: This is a prospective study where 152 consecutive B-ALL patients were analyzed for aberrant expression of T/NK cell antigens (CD1a, CD5, CD4, CD7, CD8 and CD56) by FCI. The clinical and laboratory profile of these T/NK-cell antigen-expressing B-ALL patients was statistically analyzed against conventional B-ALL patients. Results: In our B-ALL cohort, CD5, CD7 and CD56 expression were observed in one, six and nine patients, respectively. CD56-expressing B-ALL patients were predominantly children (89%) and presented as standard clinical risk (p = 0.010) disease with frequent ETV6-RUNX1 fusion (p = 0.021) positivity. On the contrary, CD7-expressing B-ALL patients were adolescent-young adult/adult-age skewed (83%) and had an adverse cytogenetic profile (p = 0.001), especially for the frequent presence of BCR-ABL1 fusion (p = 0.004) and KMT2A rearrangement (p = 0.045). CD7-expressing B-ALL patients had inferior event-free survival (p = 0.040) than their CD56-expressing counterparts, but there was no significant difference in the overall survival (p = 0.317). Conclusion: In comparison to conventional B-ALL patients, there are significant differences in the age, cytogenetic profile and event-free survival of T/NK-cell antigen-expressing B-ALL patients.http://www.sciencedirect.com/science/article/pii/S2531137920302832CD56 positive precursor B lineage acute lymphoblastic leukemiaCD7 positive precursor B lineage acute lymphoblastic leukemiaPrecursor B lineage acute lymphoblastic leukemia |
| spellingShingle | Karthik Bommannan Jhansi Rani Arumugam Venkatraman Radhakrishnan Jayachandran Perumal Kalaiyarasi Nikita Mehra Tenali Gnana Sagar Shirley Sundersingh Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell – lineage antigen expression: experience from a tertiary cancer care center Hematology, Transfusion and Cell Therapy CD56 positive precursor B lineage acute lymphoblastic leukemia CD7 positive precursor B lineage acute lymphoblastic leukemia Precursor B lineage acute lymphoblastic leukemia |
| title | Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell – lineage antigen expression: experience from a tertiary cancer care center |
| title_full | Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell – lineage antigen expression: experience from a tertiary cancer care center |
| title_fullStr | Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell – lineage antigen expression: experience from a tertiary cancer care center |
| title_full_unstemmed | Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell – lineage antigen expression: experience from a tertiary cancer care center |
| title_short | Precursor B-lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and T cell – lineage antigen expression: experience from a tertiary cancer care center |
| title_sort | precursor b lineage acute lymphoblastic leukemia patients with aberrant natural killer cell and t cell lineage antigen expression experience from a tertiary cancer care center |
| topic | CD56 positive precursor B lineage acute lymphoblastic leukemia CD7 positive precursor B lineage acute lymphoblastic leukemia Precursor B lineage acute lymphoblastic leukemia |
| url | http://www.sciencedirect.com/science/article/pii/S2531137920302832 |
| work_keys_str_mv | AT karthikbommannan precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter AT jhansiraniarumugam precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter AT venkatramanradhakrishnan precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter AT jayachandranperumalkalaiyarasi precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter AT nikitamehra precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter AT tenalignanasagar precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter AT shirleysundersingh precursorblineageacutelymphoblasticleukemiapatientswithaberrantnaturalkillercellandtcelllineageantigenexpressionexperiencefromatertiarycancercarecenter |